Longeveron to Participate in Upcoming 2022 Investor Conferences

Rhea-AI Summary

On November 29, 2022, Longeveron Inc. (NASDAQ: LGVN) announced its participation in three upcoming investor conferences. The A.G.P. Virtual Biotech Conference will be held on November 30, 2022, featuring one-on-one meetings. The Benchmark Company 11th Annual Discovery Conference is set for December 1, 2022, in New York, NY, also showcasing one-on-one meetings. Finally, Longeveron will present at the RHK 2022 Disruptive Growth Conference on December 6, 2022, at 10:40 a.m. ET in New York. A live webcast of the presentation will be available for access.

MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming investor conferences.

A.G.P.’s Virtual Biotech Conference
Format: One-on-one Meetings
Date: Wednesday, November 30, 2022
Location: Virtual

The Benchmark Company 11th Annual Discovery One-on-One Investor Conference
Format: One-on-one Meetings
Date: Thursday, December 1, 2022
Location: New York, NY

RHK 2022 Disruptive Growth Conference
Format: Company Presentation
Date: Tuesday, December 6, 2022
Location: New York, NY
Time: 10:40-11:00 a.m. ET

A live webcast of the presentation at the RHK 2022 Disruptive Growth Conference can be accessed by visiting “Events & Presentations” in the Investors section of Longeveron’s website at https://investors.longeveron.com/events-and-presentations/default.aspx. A replay of the webcast will be available shortly following the conference.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has a multi-modal mechanism of action that is pro-vascular, pro-regenerative, and anti-inflammatory, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging Frailty. Additional information about the Company is available at www.longeveron.com.

Investor Contact:

Elsie Yau
Stern IR, Inc.
212-698-8700
elsie.yau@sternir.com

Source: Longeveron Inc

FAQ

What is the date of Longeveron Inc.'s participation in the A.G.P. Virtual Biotech Conference?

Longeveron Inc. will participate in the A.G.P. Virtual Biotech Conference on November 30, 2022.

Where will the Benchmark Company 11th Annual Discovery Conference be held?

The Benchmark Company 11th Annual Discovery Conference will be held in New York, NY on December 1, 2022.

What time is Longeveron Inc.'s presentation at the RHK 2022 Disruptive Growth Conference?

Longeveron Inc. will present at the RHK 2022 Disruptive Growth Conference on December 6, 2022, at 10:40 a.m. ET.

How can I access the webcast for Longeveron Inc.'s presentation at the RHK conference?

The webcast for Longeveron Inc.'s presentation can be accessed from the 'Events & Presentations' section of their website.

What is the focus of Longeveron Inc.'s regenerative medicine products?

Longeveron Inc. focuses on developing regenerative medicines to address unmet medical needs, particularly using their Lomecel-B™ therapy for various diseases.